Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

Slides:

Advertisements

Similar presentations

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Advertisements

Purpose To determine whether metoprolol controlled/extended release

Robertson JFR et al. J Clin Oncol 2009;27(27):

1 Efficacy of Testosterone Transdermal System (TTS) for Treatment of HSDD in Surgically Menopausal Women on Concomitant Estrogen Daniel Davis, MD, MPH.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.

Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.

Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.

Progesterone and Traumatic Brain Injury. from: Progesterone is a female hormone important for the regulation of.

A Randomized Phase II Study of OGX-011 in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Design: A randomized, prospective, double-blind cohort followed for 16 weeks RenehaVis Original Study 50 DMW 50 HMW 50 LMW 50 Placebo.

NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.

Prostate Support Group Dr Duncan McLaren Consultant Oncologist.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease (AD) by memantine: a pooled data analysis Gauthier S., Loft.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.

4S: Scandinavian Simvastatin Survival Study

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.

CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.

Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.

Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:

Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation Michael Camilleri, M.D., Rene Kerstens, M.Sc., An Rykx, Ph.D., and Lieve Vandeplassche,

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Number Needed To Treat (NNT)

The LIVES Sub-analysis

METHODS and STATISTICS

Palumbo A et al. Proc ASH 2012;Abstract 200.

Clinical Trials — A Closer Look

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Neal B, et al. Diabetes Care 2015;38:403–411

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Martha Carvour, MD, PhD March 2, 2017

ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A

UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES

Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)

Intervista a Lucio Crinò

How the Latest Data in MDD Can Guide Treatment Decisions:

Clinical Trials in STS Shreyaskumar Patel, M.D.

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Management of perioperative hypertension

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

FX006 Pivotal Ph 2b Data September , 2015

Cancer-Associated Thrombosis

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Reducing Risk for CV Outcomes

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

The American College of Cardiology Presented by Dr. Timothy Henry

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

B-FREE Trial B-FREE Trial Summary.

Treatment Advances for RA

Late-Breaking Data on LDL-C Reduction

Translating Data From Trial to Practice

Presentation transcript:

Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

Primary Endpoint AUA BPH Symptom Score Single injection results after median 42 months post-treatment (range 24 months to 65 months) Mean improvement 5.3 points (p<.025 vs placebo) First-line treatment with fexapotide mean improvement 7.16 points (p<.02 vs placebo)

BPH Improvement

AUA BPH Symptom Score Patient Responder Rate Statistically significant higher proportion of long-term improved patients in AUA BPH Symptom Score (primary outcome variable) after a single injection in fexapotide treated subjects (64%) vs controls (p<.005)

Nocturia Median 42 months post-single injection treatment Stabilization or improvement 87% (p<.03 vs placebo)

Surgery for BPH 1.7% in 2 years after 1-2 injections of fexapotide (p<.02 vs placebo)

Fexapotide Lowered Cancer Risk Phase 2 US data showing reduced progression of low grade prostate cancer in fexapotide treated patients This is in contrast to elevated cancer risk for some approved BPH oral medications

Nymox Fexapotide Advantages Safe drug with durable efficacy Office-based 1-2 minute injection Single painless injection: no sedation, no anesthesia No sexual side effects (commonly seen with older approved BPH medications) No cardiovascular or hormonal side effects (commonly seen with older approved BPH medications) Decreased cancer risk (Phase 2 data) (vs increased risk seen with older approved BPH medications)

Nymox Fexapotide Safety Profile Superior to BPH approved medications No sexual or cardiovascular side effects No hormonal side effects No increased risk of prostate cancer (decreased risk with fexapotide, Phase 2)

Nymox Fexapotide Efficacy Profile Highly durable effect: Single painless office injection with long-term benefit After a single injection with fexapotide, the majority of patients in Phase 3 pivotal studies required no further oral medications or surgery for up to 5.4 years (median 42 months). First-line single treatment after 3.5 years: 7.16 point mean improvement